Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Interventional Cardiology|December 13, 2005
One-year clinical outcomes after complete arterial coronary revascularizationHartmut Oster, Franz Schwarz, Hans Störger, et al.
Leukemia Research|January 5, 2002
Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemiaAnke Müller, Karin Lange, Timo Gaiser, et al.
Journal of Interventional Cardiology|December 13, 2005
Percutaneous saphenous vein graft interventions with and without distal filter wire protectionManfred Hofmann, Hans Störger, Franz Schwarz, et al.
Breast Cancer Research : BCR|October 10, 2007
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring studyMarc van de Vijver, Michael Bilous, Wedad Hanna, et al.
Diagnostic Pathology|March 14, 2018
Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancerAndreas H Scheel, Frédérique Penault-Llorca, Wedad Hanna, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 7, 2012
HER2 testing in gastric cancer: a practical approachJosef Rüschoff, Wedad Hanna, Michael Bilous, et al.
Journal of Interventional Cardiology|November 18, 2004
Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to interventionJürgen Haase, Rusen Bayar, Matthias Hackenbroch, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|December 6, 2005
Comparison of a centered 32P source wire system with a noncentered 90Sr/Y brachytherapy system for intracoronary beta-radiation following PCI of diffuse in-stent restenosisJürgen Haase, Peter von Neumann-Cosel, Michael Damm, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2023
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trialMarcus Schmidt, Ulrike Nitz, Toralf Reimer, et al.
Pageof 3